Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Users of Invader DNA Analyte Specific Reagents (US)(?)

Council Members in this Study Group: 21

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

John Waugh, Director of System Laboratory Operations, Henry Ford Health SystemJohn Waugh
Director of System Laboratory Operations
Henry Ford Health System

John Waugh is the Director of System Laboratory Operations at Henry Ford Health System, the 12th largest US hospital laboratory, research & and academic medical center in Detroit, MI. Mr. Waugh has expertise in new and emerging clinical and molecular diagnostic systems, including products and services...

Robert Boorstein, MD, PhD
Director of Pathology
Bellevue Hospital Center

Robert Boorstein, MD, PhD, is the Director of Pathology at Bellevue Hospital and an Associate Professor in the Department of Pathology at New York University School of Medicine. He is also the Medical Director for Pathology and Laboratory Medicine of the South Manhattan Healthcare Network and Northern...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Impact of restrictions on gifts to MD's on prescribing patterns | 08-21-2007
Analysis of: NY bill would require pharmas to report MD gifts | www.fiercehealthcare.com
Author: Robert Boorstein, MD, PhD, Director of Pathology, Bellevue Hospital Center

Pharmaceutical companies spend over $10,000 per physician on direct gifts and similar activities.  These activities are designed to influence prescribing patterns, and most certainly do.  Monitoring sales of drug classes as drugs come off patent, as in anti allergy medications, drugs for acid...

Carrots and sticks to improve patient safety. | 08-21-2007
Analysis of: By 2008, Medicare won't pay for hospital errors | www.fiercehealthcare.com
Author: Robert Boorstein, MD, PhD, Director of Pathology, Bellevue Hospital Center

The last several years as seen the growth of financial incentives to stimulate improvements in patient safety and patient outcomes.  Clearly society has an interest in improving patient safety, and aligning providers and payers financially is a laudable goal. The use of denied payments raises the...

Is this the future of laboratory automation | 02-28-2007
Author: Robert Boorstein, MD, PhD, Director of Pathology, Bellevue Hospital Center

How much will Abbott contribute to bottom line of GE.What is future of Abbott.

Implications of new breast cancer prognostic methodology | 02-09-2007
Analysis of: FDA Approves Test | online.wsj.com
Author: Robert Boorstein, MD, PhD, Director of Pathology, Bellevue Hospital Center

Approval of the Mammaprint is a significant advance clinically, as it is the first FDA approved gene expression test for breast cancer.  If it is widely accepted, it would represent one of the highest value cancer diagnostic products.  The technology would presumably be extended to other common...

Non genetic factors determining warfarin dose | 01-23-2007
Analysis of: DNA tests to determine warfarin dose | news.yahoo.com
Author: Robert Boorstein, MD, PhD, Director of Pathology, Bellevue Hospital Center

Using DNA tests to predict appropriate warfarin dosages clearly has market potential.   However, it is yet to be proven that such testing will significantly reduce the trial and error basis of such, and the article discusses trials that are underway.It should be noted that the causes of underdoses...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Lab, Academic Medical Center
  • Academic Institution*
  • Laboratory, Independent
  • Non-Academic Community Hospital or Clinic
  • Lab, Non-Academic/Community Hospital
  • Medical Equipment & Supplies Manufacturer

Most Common Job Types:

  • Director
  • Research Scientist
  • Physician - Director
  • Physician - Attending Physician
  • Physician - Department Chair
  • Professor
  • President
  • Assistant Professor

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-05T01:45:24.617